

## PATENT

DOCKET NO.: ISIS0053-100 (RTS-0182)

## In the Claims:

Please cancel claims 1, 2, 4-10, and 12-15 without prejudice to their presentation in another application, and add new claims 21-39 as follows:

1-20. (cancelled).

21. (new) An oligomeric compound up to 50 nucleobases in length comprising SEQ ID NO:73, or a pharmaceutically acceptable salt thereof.

22. (new) The compound of claim 21 which is an oligonucleotide.

23. (new) The compound of claim 22 wherein the oligonucleotide comprises at least one modified internucleoside linkage.

24. (new) The compound of claim 23 wherein the modified internucleoside linkage is a phosphorothioate linkage.

25. (new) The compound of claim 22 wherein the oligonucleotide comprises at least one modified sugar moiety.

26. (new) The compound of claim 25 wherein the modified sugar moiety is a 2'-O-CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, 2'-O-CH<sub>3</sub>, or 2'-F moiety.

27. (new) The compound of claim 26 wherein the modified sugar moiety is a 2'-O-CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub> moiety.

28. (new) The compound of claim 22 wherein the oligonucleotide comprises at least one modified nucleobase.

## PATENT

DOCKET NO.: ISIS0053-100 (RTS-0182)

29. (new) The compound of claim 28 wherein the modified nucleobase is a 5-methylcytosine.
30. (new) The compound of claim 22 wherein the oligonucleotide is a chimeric oligonucleotide.
31. (new) The compound of claim 30 wherein the chimeric oligonucleotide comprises 2'-O-CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub> wings and a deoxy gap.
32. (new) The compound of claim 21 wherein the pharmaceutically acceptable salt is a sodium salt or a potassium salt.
33. (new) A composition comprising the compound of claim 21 and a pharmaceutically acceptable carrier or diluent.
34. (new) The composition of claim 33 wherein the oligomeric compound is an oligonucleotide.
35. (new) The composition of claim 33 further comprising a colloidal dispersion system.
36. (new) The composition of claim 34 further comprising another oligonucleotide.
37. (new) A method of inhibiting the expression of damage-specific DNA binding protein 1, p127 in a cell or a tissue comprising contacting the cell or tissue *in vitro* with the compound of claim 21, wherein the expression of damage-specific DNA binding protein 1, p127 is inhibited.
38. (new) A method of detecting the presence of damage-specific DNA binding protein 1, p127 in a cell or a tissue comprising contacting the cell or tissue *in vitro* with the compound of claim 21 and detecting the presence of the compound.

**DOCKET NO.: ISIS0053-100 (RTS-0182)**

**PATENT**

39. (new) A kit comprising the compound of claim 21.